IMMUNOCELLULAR THERAPEUTICS, LTD. (NYSEMKT:IMUC) Files An 8-K Results of Operations and Financial Condition

Item2.02.

On March9, 2017, ImmunoCellular Therapeutics, Ltd. (the Company)
issued a press release announcing financial results for the
fourth quarter and year ended December31, 2016. A copy of this
press release is attached as Exhibit 99.1.

This information, including exhibits attached hereto and the
information under item 9.01 below, shall not be deemed filed for
the purposes of Section18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act), or otherwise subject to the
liabilities of that section. This information shall not be deemed
to be incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act.

About IMMUNOCELLULAR THERAPEUTICS, LTD. (NYSEMKT:IMUC)

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

IMMUNOCELLULAR THERAPEUTICS, LTD. (NYSEMKT:IMUC) Recent Trading Information

IMMUNOCELLULAR THERAPEUTICS, LTD. (NYSEMKT:IMUC) closed its last trading session up +0.09 at 2.63 with 87,655 shares trading hands.